For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

How Tafinlar + Mekinist works: Dual targets. One pathway.

A dual-targeting approach that simultaneously hits two key drivers of the MAP-K pathway1,2

Tafinlar® (dabrafenib) and Mekinist® (trametinib) mechanism of action (MoA): MAP-K Pathway.  Blocking MEK in addition to BRAF is thought to:

  • Reduce the risk of treatment resistance1

  • Improve response rates over monotherapy3

The only combination approved to target
the BRAF V600 mutation in NSCLC2

References: 1. Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S. BRAF alterations as therapeutic targets in non–small-cell lung cancer. J Thorac Oncol. 2015;10(10):1396-1403. 2. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 3. Luke JJ, Ott PA. New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy. Drug Healthc Patient Saf. 2014;6:77-88.